Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195360 | 0.84 | BRAF (0.71) | BRAFMAPK14MEN1KMT2AKDR | |
| SCHEMBL4195736 | 0.83 | KDR (0.67) | MEN1KMT2AKDRCSNK2A2CSNK2B | |
| SCHEMBL4199921 | 0.83 | MEN1 (0.56) | BRAFMEN1KMT2AKDRLMNA | |
| SCHEMBL4198743 | 0.83 | BRAF (0.72) | BRAFMAPK14MEN1KMT2ACSNK2A2 | |
| SCHEMBL4205668 | 0.82 | KDR (0.63) | BRAFKDRCSF1R | |
| SCHEMBL4195622 | 0.81 | BRAF (0.59) | BRAFMAPK14KDRCSF1R | |
| SCHEMBL4205675 | 0.78 | KIT (0.64) | BRAFMEN1KMT2AKDRLMNA | |
| SCHEMBL4188378 | 0.77 | BRAF (0.57) | BRAFMAPK14KDRMAPK1CSF1R | |
| SCHEMBL4194989 | 0.74 | BLM (0.54) | BRAFKDRCSF1R | |
| SCHEMBL4195978 | 0.72 | BRAF (0.76) | BRAFMEN1KMT2AKDRCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | WYETH (US) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | BRAF, ARAF, RAF1 | BRAF 1/4885MAPK14 498/4885MEN1 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.